Imugene Limited

IMU

AU000000IMU9

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:22 2024-06-14 EDT			5-day change	1st Jan Change
0.058 ^AUD	0.00%		-3.33%	-47.27%

04-16	Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	MT
04-16	Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.	CI

Imugene Limited Announces Cessation of Otto Buttula as Director

January 17, 2016 at 05:47 pm

Imugene Limited announced cessation of Otto Buttula as director, effective 15 January 2016.

Latest news about Imugene Limited

Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	04-16	MT
Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.	04-15	CI
Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients	04-15	CI
Imugene Commences Enrolment for Cholangiocarcinoma Expansion Study	04-14	MT
Imugene Secures Patent for Oncolytic Virotherapy CF33 in China	04-03	MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	03-19	MT
Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment	03-11	CI
Imugene's Phase 1 onCARlytics Trial to Commence Combination Arm Treatment	03-10	MT
Imugene Widens Per-Share Loss in H1 FY24 to AU$0.01 on Higher General, R&D Spending	02-28	MT
Imugene Reports H1 FY24 Loss Widens as Expenses Grow	02-28	MT
Imugene Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Imugene’s Phase 1 onCARlytics Trial Doses First Patient in Intravenous Monotherapy Arm	02-14	MT
Esken's Southend Airport faces further allegations	01-23	AN
MaxCyte Inks Platform License Deal With Cancer Medicine Developer Imugene	01-23	MT
Australian Shares End Five-Day Losing Streak Amid Market Conviction of Early US Fed Pivot	01-19	MT
Imugene’s VAXINIA Metastatic Advanced Solid Tumors Trial Doses First Patients in Higher Dose Cohorts; Shares Up 10%	01-18	MT
Imugene's Vaxinia Trial Shows Positive Signs	01-18	MT
Imugene to Open Phase Two Colorectal Cancer Trial in the UK, Australia	12-06	MT
Imugene to Secure European Patent for Cancer Vaccine	12-05	MT
FDA Grants Fast Track Designation for Imugene's CF33-hNIS in Bile Duct Cancer MAST Program	11-28	MT
US FDA Transfers Cancer Medication Application to Imugene	23-09-28	MT
Imugene Raises AU$18 Million in Share Purchase Plan	23-09-25	MT
Imugene Limited(ASX:IMU) dropped from S&P/ASX 200 Index	23-09-18	CI
Imugene Appoints Medical Chief	23-09-04	MT
Imugene Limited Appoints Paul Woodard as Chief Medical Officer	23-09-03	CI

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the bodyâs immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

Sector

Biotechnology & Medical Research

Calendar

2024-08-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.058 AUD

Average target price

0.3533 AUD

Spread / Average Target

+509.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMUGENE LIMITED	-47.27%	281M
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research

Imugene Limited

Equities

IMU

AU000000IMU9

Biotechnology & Medical Research

Imugene Limited Announces Cessation of Otto Buttula as Director

Latest news about Imugene Limited

Chart Imugene Limited

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research